SEC filings and other documents

Rese-cel delivers durable, safe remissions in myositis, supporting rapid outpatient adoption.

Durable, safe cell therapy shows promise for autoimmune diseases, enabling outpatient access.

Rese-cel demonstrates robust efficacy and safety, enabling scalable outpatient therapy for autoimmunity.

Automated CAR T manufacturing and preconditioning-free regimens drive scalable autoimmune therapy.

Rese-cel delivers durable, safe, and scalable CAR T therapy for autoimmune diseases.

Promising clinical progress and $150M financing position the company for pivotal milestones.

Rese-cel delivers durable, safe, outpatient CAR T therapy for autoimmune diseases at scale.

Rese-cel delivers transformative, outpatient-ready CAR T therapy for autoimmune diseases.

Automated CAR T manufacturing and no preconditioning may revolutionize autoimmune therapy.

Automated manufacturing and outpatient CAR-T therapy drive scalability and cost efficiency.

Pivotal CD19-CAR T trials show strong efficacy, safety, and outpatient potential in autoimmunity.

Clinical and manufacturing advances drive progress, with strong cash runway into late 2026.

Rese-cel delivers transformative, drug-free responses in refractory autoimmune diseases.

Pivotal Rese-cel trials show strong efficacy, safety, and scalable outpatient potential.

Single-arm trials and outpatient focus drive a strong commercial outlook for autoimmune CAR-T.

Outpatient CAR-T for myositis offers strong efficacy, safety, and a viable business model.

Pivotal trials advance for curative autoimmune therapy, with outpatient, one-time dosing on the horizon.

Strong clinical and regulatory momentum for rese-cel, with robust cash position into 2026.

October data could secure first-to-market status in myositis and reshape autoimmune therapy.

Cash runway extended into 2H26 as clinical and regulatory milestones advance for rese-cel.

Rese-cel demonstrates robust efficacy and safety in autoimmune diseases, targeting 2027 approval.

FDA-aligned Resocel trials advance rapidly, with key data and milestones expected this year.

Q1 2025 net loss widened to $35.9M as R&D spending increased for clinical programs.

Strong RESET trial progress and robust cash position support 2025 milestones.